Abstract: PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.

Abstract: A method, apparatus, and stored instructions are provided for the removal of redundant GROUP BY and/or DISTINCT. Every table in the FROM clause of the query block must be a qualified table for the GROUP-BY clause or the DISTINCT keyword in the SELECT clause of the query block to be removed. A table Tx that satisfies at least one of the following two conditions is referred to as a qualified table: (1) Tx has a non-null unique column Tx.u that appears on the GROUP BY clause or the SELECT clause that contains a DISTINCT keyword and (2) There is a qualified table Ty and Ty has a filtering join with Tx.

Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-1, and/or PD-L2 activity (e.g., persistent infectious diseases autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.

Abstract: The present invention relates to methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors, as well as diagnostic, prognostic, therapeutic methods and compositions related thereto.

Abstract: A method, apparatus, and stored instructions are provided for transforming an initial query by eliminating a subquery nested within the initial query. The initial query may include an outer query that references a first instance of a particular data object. The initial query may also include set operator(s). At least a particular set operator may include a particular subquery that references a different instance of the particular data object. A query processor may transform the initial query to a transformed query that excludes the particular set operator and the particular subquery. The transformed query may instead include an added predicate that is based at least in part on the particular subquery. The added predicate may reference the first instance of the particular data object without referencing the different instance of the particular data object. The transformed query may be used for query execution instead of the initial query.

Abstract: This disclosure relates to the genetic modification of DNMT3A gene in immune cells. In certain embodiments, the modified immune cells may be used in adoptive T cells therapies to enhance immune responses against cancer or chronic infections. In certain embodiments, the disclosure relates to deleting, changing, or inserting nucleotides within the DNMT3A gene in immune cells, e.g., human CD8 T cells, such that the DNMT3A gene product does not function for methylation. In certain embodiments, modification of the DNMT3A gene provides an improvement in antigen-specific T cells functions and/or an enhancement of the longevity of the cells.

Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.

Abstract: PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.

Abstract: A method and apparatus for outer-joined and/or cross-joined table elimination for duplicate-insignificant queries is provided. A query block of a query specifies a join between a first table and a second table. The join is one of an outer join and a cross join. A first determination is made that the query block contains no references to the second table to be processed after the join. A second determination is made that the query block is duplicate-insignificant. In response to making the first determination and the second determination, the query block is transformed into a transformed query, where the second table is eliminated from a corresponding query block in the transformed query.

Abstract: Techniques herein optimize sort-merge join method for a band join. In an embodiment, for a query comprising a query block specifying a join between a first table and a second table, a band join condition is detected between the first table and the second table. Once the band join condition in detected, an execution plan is generated and executed. The execution of the execution plan includes: for a first row of at least a subset of first sorted rows, scanning second rows from a set of second sorted rows, joining each of said second rows with said first row, and ceasing to scan when encountering a row from the second sorted rows that falls outside a bound of said band join condition. Techniques also include parallelizing a workload by overlapping the distribution of rows to the same slave process and computing cost and cardinality estimation for enhanced band join.

Abstract: Attributes and semantics of duplicate insignificance that are inherent or inferred in a database language statement are detected. Also, a join operation that is inherent or inferred in the database language statement is detected and examined for join semantics. The join semantics specifies or refers to a driving table to be subjected to a hash join operation that may populate one or more hash buckets. The optimizer and the execution layers may use cost estimation or heuristics to assign the left and right table roles to the tables involved in the join. The hash join operation removes left table duplicates during population of the hash buckets, resulting in full or partial duplicate elimination that occurs during the hash join operation.

Abstract: Methods, stored instructions, and computer systems are described for selecting an OR-expansion state of a query. A query processor accesses a certain query and a control parameter. The certain query comprises disjunctive predicates, and the control parameter indicates a certain procedure of a plurality of alternative stored procedures for expanding queries comprising disjunctive predicates into semantically equivalent candidate queries comprising combinations of subqueries. Based at least in part on the control parameter, the query processor selects the certain procedure to expand the certain query into one or more certain semantically equivalent candidate queries, each comprising a different combination of two or more subqueries. The query processor causes cost-based evaluation of subject queries, including the certain query and the one or more certain semantically equivalent candidate queries.

Abstract: PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist. Methods are also disclosed for determining the efficacy of a PD-1 antagonist in a subject administered the PD-1 antagonist. In some embodiments, these methods include measuring proliferation of memory B cells in a sample from a subject administered the PD-1 antagonist.

Abstract: PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist. Methods are also disclosed for determining the efficacy of a PD-1 antagonist in a subject administered the PD-1 antagonist. In some embodiments, these methods include measuring proliferation of memory B cells in a sample from a subject administered the PD-1 antagonist.

Abstract: The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.

Abstract: Antibodies or antibody fragments, wherein the antibody or the fragment binds HA domain of influenza virus (e.g. H1N1, H5N1, or both). Also described are cloned human antibodies that bind influenza.

Abstract: The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.

Abstract: Antibodies that bind with high affinity to swine H1N1 virus are described. In vivo experiments showed that one such antibody is able to fully protect mice challenged with a lethal dose of swine H1N1 virus. The antibody is also able to cure mice in a therapeutic setting when treated as late as up to 60 hours (2.5 days) after infection with swine H1N1 virus. Also described are recombinant forms of this antibody.

Abstract: Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided.

Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.